Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Eli Lilly and Co News & Analysis
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
markets
June 2025 US stock market outlook: Has the storm passed?
Be wary of the recent complacency; there’s turbulent water ahead before the skies clear.
markets
US stock market outlook: Where we see opportunities in Q2
A bear market in AI stocks leads to more attractive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,321.10 | 10.80 | -0.12% |
CAC 40 | 8,206.87 | 51.99 | -0.63% |
DAX 40 | 24,151.13 | 178.90 | -0.74% |
Dow JONES (US) | 46,602.33 | 322.41 | -0.69% |
FTSE 100 | 9,533.90 | 106.91 | 1.13% |
HKSE | 25,781.77 | 245.78 | -0.94% |
NASDAQ | 22,725.88 | 227.78 | -0.99% |
Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
S&P 500 | 6,698.82 | 36.53 | -0.54% |
S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
SSE Composite Index | 3,913.76 | 2.57 | -0.07% |